Skip to main content
OpenTrials
Completed

NCT Number: NCT00755859

"Steroids and Azathioprine Versus Steroids Alone in IgAN"

In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant. A six-month course of steroid therapy may be not enough to ensure a stable remission. The investigators hypothesized that a more aggressive treatment may obtain long-term better results. The investigators conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In 1999, we published a multicenter, randomized, controlled trial, which compared a 6-month steroid course with supportive therapy in 86 patients with IgAN. After 5 years of follow-up, the risk of a 50% increase in plasma creatinine from baseline was significantly lower in the treated patients; proteinuria also decreased. However, the effect of steroids seemed to diminish over time. The difference in renal survival was particularly striking up till the third year, but then remained constant. We hypothesised that a six-month course of steroid therapy is not enough to ensure a stable remission, and a more aggressive treatment may be required to obtain long-term better results. At this regard, some studies of combined treatment with corticosteroids and azathioprine found that treatment was effective in preserving renal function and in reducing proteinuria. However, these studies did not clarify whether azathioprine added further benefit to steroids in the long term. We conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • biopsy proven IgA nephropathy
  • creatinine ≤ 2.0 mg/dl for at least three months
  • proteinuria ≥ 1.0 g/day for at least three months

Exclusion criteria

  • treatment with steroids or cytotoxic drugs during the previous three years
  • contraindications to steroids or azathioprine
  • Henoch-Schöenlein purpura
  • diabetes mellitus
  • severe hypertension (diastolic blood pressure > 120 mmHg)
  • lupus erythematosus systemicus
  • malignancies
  • active peptic-ulcer disease
  • pregnancy
  • viral hepatitis or other infections

Treatment and study plan

steroids plus azathioprine

Drug

methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months

Other names: solumedrol, deltacortene, azatioprina

Steroids

Drug

methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months

Other names: solumedrol, deltacortene

Primary outcomes

  1. progression of renal disease, estimated by the time to 50% increase in plasma creatinine from baseline.

    Time frame: Every month for the first six months, then six months

Secondary outcomes

  1. evolution of proteinuria over time

    Time frame: every months for the first six months and then every six months

  2. safety

    Time frame: every months for the first six months and then every six months

Sponsors and collaborators

Lead sponsor

A. Manzoni Hospital

Other

Registry information

Official study title

Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial.

Important dates

Study start
1998
Primary completion
2004
Study completion
2007
First posted
Sep 19, 2008
Registry last updated
Sep 19, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.